Poolbeg Pharma PLC (POLB) - Total Liabilities
Based on the latest financial reports, Poolbeg Pharma PLC (POLB) has total liabilities worth GBX1.34 Million GBX (≈ $163.16 USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See POLB working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Poolbeg Pharma PLC - Total Liabilities Trend (2021–2025)
This chart illustrates how Poolbeg Pharma PLC's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see POLB current and non-current assets.
Poolbeg Pharma PLC Competitors by Total Liabilities
The table below lists competitors of Poolbeg Pharma PLC ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Hansard Global Plc
LSE:HSD
|
UK | GBX1.42 Billion |
|
Maven Income And Growth Vct Plc
LSE:MIG1
|
UK | GBX449.00K |
|
Michelmersh Brick Holdings Plc
LSE:MBH
|
UK | GBX36.10 Million |
|
Jade Leader Corp
V:JADE
|
Canada | CA$456.03K |
|
Insplorion AB
ST:INSP
|
Sweden | Skr3.60 Million |
|
Aurora Solar Technologies Inc
V:ACU
|
Canada | CA$4.13 Million |
|
Corero Network Security plc
LSE:CNS
|
UK | GBX13.32 Million |
|
Black Widow Resources Inc
V:BWR
|
Canada | CA$1.46 Million |
Liability Composition Analysis (2021–2025)
This chart breaks down Poolbeg Pharma PLC's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See net asset quality index of Poolbeg Pharma PLC to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 6.17 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.16 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.13 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Poolbeg Pharma PLC's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Poolbeg Pharma PLC (2021–2025)
The table below shows the annual total liabilities of Poolbeg Pharma PLC from 2021 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | GBX1.34 Million ≈ $163.16 |
+37.68% |
| 2024-12-31 | GBX974.00K ≈ $118.51 |
-1.22% |
| 2023-12-31 | GBX986.00K ≈ $119.97 |
+2.07% |
| 2022-12-31 | GBX966.00K ≈ $117.53 |
+120.55% |
| 2021-12-31 | GBX438.00K ≈ $53.29 |
-- |
About Poolbeg Pharma PLC
Poolbeg Pharma PLC, a clinical-stage biopharmaceutical company, engages in developing immunotherapy for cancer in the United Kingdom. The company develops POLB 001, which is completed phase 1 clinical study for cancer immunotherapy-induced cytokine release syndrome; and phase 2 for the treatment of influenza. It also developing oral encapsulated GLP-1R agonist for obesity and diabetes treatment; … Read more